Original Article
Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea
N Engl J Med 2004; 350:647-654February 12, 2004
- Abstract
Background
B-type natriuretic peptide levels are higher in patients with congestive heart failure than in patients with dyspnea from other causes.
Methods
We conducted a prospective, randomized, controlled study of 452 patients who presented to the emergency department with acute dyspnea: 225 patients were randomly assigned to a diagnostic strategy involving the measurement of B-type natriuretic peptide levels with the use of a rapid bedside assay, and 227 were assessed in a standard manner. The time to discharge and the total cost of treatment were the primary end points.
Results
Base-line demographic and clinical characteristics were well matched between the two groups. The use of B-type natriuretic peptide levels reduced the need for hospitalization and intensive care; 75 percent of patients in the B-type natriuretic peptide group were hospitalized, as compared with 85 percent of patients in the control group (P=0.008), and 15 percent of those in the B-type natriuretic peptide group required intensive care, as compared with 24 percent of those in the control group (P=0.01). The median time to discharge was 8.0 days in the B-type natriuretic peptide group and 11.0 days in the control group (P=0.001). The mean total cost of treatment was $5,410 (95 percent confidence interval, $4,516 to $6,304) in the B-type natriuretic peptide group, as compared with $7,264 (95 percent confidence interval, $6,301 to $8,227) in the control group (P=0.006). The respective 30-day mortality rates were 10 percent and 12 percent (P=0.45).
Conclusions
Used in conjunction with other clinical information, rapid measurement of B-type natriuretic peptide in the emergency department improved the evaluation and treatment of patients with acute dyspnea and thereby reduced the time to discharge and the total cost of treatment.
Media in This Article
Figure 1
Cumulative Frequency Distribution Curve for the Time to Discharge of Patients in the B-Type Natriuretic Peptide Group as Compared with Those in the Control Group.Table 1
Base-Line Characteristics of the Patients.Article Activity
- Article
Heart failure is a major public health problem. Currently, more than 15 million patients have heart failure in North America and Europe, with nearly 1.5 million new cases every year.1-5 Heart failure is the most frequent cause of hospitalization among people older than 65 years of age, and these hospitalizations are an important part of the enormous cost of the disease. Over the past decade, the rate of hospitalization for heart failure has increased by 159 percent.3 It is estimated that in the United States in 2001, the direct cost of the care of patients with heart failure exceeded $24 billion.3 Therefore, cost-effective management is of paramount importance. However, the rapid and accurate differentiation of heart failure from other causes of dyspnea remains a clinical challenge, especially in the emergency department.4-10 After evaluating a patient's symptoms, conducting a physical examination, and performing electrocardiography and chest radiography, the clinician is often left with considerable diagnostic uncertainty, which results in misdiagnosis and delays the initiation of appropriate therapy.7,10 In addition, the misdiagnosis of heart failure causes morbidity and increases the time to discharge and the cost of treatment, because the use of a treatment strategy for other conditions, such as chronic obstructive pulmonary disease, may be hazardous to patients with heart failure, and vice versa.6,8,9
Observational studies have suggested that, when used in conjunction with other clinical information, B-type natriuretic peptide levels may be useful in establishing or ruling out the diagnosis of heart failure in patients with acute dyspnea.6,7,10-14 B-type natriuretic peptide is a 32-amino-acid polypeptide secreted by the cardiac ventricles in response to ventricular volume expansion and pressure overload.15-17 The levels of B-type natriuretic peptide are elevated in patients with left ventricular dysfunction, and the levels correlate with both the severity of symptoms and the prognosis.3,6,7,9-19 However, the clinical effect of this diagnostic test on the evaluation and treatment, outcome, and cost of treatment of patients with dyspnea is unknown. Therefore, we performed a randomized, controlled trial to test the hypothesis that a diagnostic strategy guided by the rapid measurement of B-type natriuretic peptide levels would improve the evaluation and care of patients with acute dyspnea who present to the emergency department and would thereby reduce the time to discharge and the total cost of treatment.
Methods
Setting and Study Population
The B-Type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) Study was a prospective, randomized, controlled, single-blind study conducted in the emergency department of the University Hospital in Basel, Switzerland. Patients were evaluated in the emergency department by at least two physicians: a resident in internal medicine and an internal-medicine specialist. The study investigators were not directly involved in patient care in the emergency department, nor did they have any influence on the decision to discharge patients from the ward. The study was carried out according to the principles of the Declaration of Helsinki and approved by the local ethics committee. Written informed consent was obtained from all participating patients.
We screened 665 consecutive adults who presented to the emergency department between May 2001 and April 2002. Eligible patients were those who had acute dyspnea as the primary symptom, with no obvious traumatic cause of dyspnea. Patients with severe renal disease (defined by a serum creatinine level of more than 250 μmol per liter [2.8 mg per deciliter]), patients with cardiogenic shock, and patients who requested an early transfer to another hospital were excluded. There were no limitations to entry according to the time of day at which patients arrived in the emergency department or the availability of research staff.
A total of 452 patients were enrolled in the trial, and group assignment was accomplished with the use of a computer-generated randomization scheme in a 1:1 ratio without stratification. A total of 225 patients were randomly assigned to be evaluated with the use of a diagnostic strategy that included the rapid bedside measurement of B-type natriuretic peptide levels, and 227 were assigned to be evaluated with the use of the conventional diagnostic strategy. The B-type natriuretic peptide was not measured for clinical purposes by clinicians who treated patients in the control group, nor was it measured serially in either of the groups.
Routine Clinical Assessment
All patients underwent an initial clinical assessment that, in general, included a clinical history taking, a physical examination, electrocardiography, pulse oximetry, blood tests, and chest radiography. Echocardiography and pulmonary-function tests were strongly recommended on an outpatient basis for patients who were released from the emergency department, as well as for the patients who were admitted.
Measurement and Interpretation of B-Type Natriuretic Peptide Levels
During the initial evaluation, at the time of venipuncture for routine blood tests, a 5-ml specimen of venous blood was collected in tubes containing potassium EDTA. During a 15-minute period, B-type natriuretic peptide was measured with the use of a rapid fluorescence immunoassay (Biosite Diagnostics). The precision, analytic sensitivity, and stability of the system have been described previously.14,18 In brief, the coefficient of variation within a given assay has been reported to be 9.5 percent, 12.0 percent, and 13.9 percent for levels of 28.8, 584.0, and 1180.0 pg per milliliter, respectively, and the coefficient of variation among assays is known to be 10.0 percent, 12.4 percent, and 14.8 percent, respectively.14,18 The limit of analytic sensitivity was less than 5.0 pg per milliliter, with a measurable range of 0 to 1300 pg per milliliter.
In the group in which B-type natriuretic peptide levels were measured, diagnostic and therapeutic decisions were not based on the B-type natriuretic peptide levels alone; instead, this information was considered in the context of the other clinical information obtained and the physicians' clinical impressions, as previously described.20 In brief, we used a B-type natriuretic peptide level of 100 pg per milliliter to separate dyspnea caused by heart failure from other causes of dyspnea.3,6,7,9-13,20 In patients with a B-type natriuretic peptide level below 100 pg per milliliter, the diagnosis of heart failure was considered unlikely, and alternative causes of dyspnea had to be investigated. In patients with a B-type natriuretic peptide level of more than 500 pg per milliliter, heart failure was considered the most likely diagnosis, and rapid therapy with diuretics, nitroglycerin, angiotensin-converting–enzyme inhibitors, and morphine was recommended. For patients with B-type natriuretic peptide levels between 100 and 500 pg per milliliter, the protocol recommended the use of clinical judgment and possible further diagnostic testing to rule out stable base-line left ventricular dysfunction and other conditions as the real cause of acute dyspnea.3,6,7,9-14,20 No formal adjustment was recommended regarding the B-type natriuretic peptide cutoff values in patients with mild chronic kidney disease. Patients in the control group were evaluated and treated according to the most recent clinical guidelines.4,5
End Points
The time to discharge and the cost of treatment were the primary end points of the study. Secondary end points included in-hospital and 30-day mortality. The time to discharge was defined as the interval from presentation at the emergency department to discharge. Patients who died in the hospital were excluded from the calculation of this end point. Since ratios of costs to charges have not been defined for the majority of services and departments at our institution, hospital charges were used as the most appropriate estimate of the true costs.21,22 To avoid an imbalance owing to differences in reimbursement or charges associated with different types or classes of insurance, charges were standardized according to the actual rates for patients with general insurance who were living in Basel. The current reimbursement for the measurement of B-type natriuretic peptide in Switzerland ($47) was used. The time to treatment was defined as the interval from presentation to the initiation of the appropriate therapy — other than bed rest and supplemental oxygen — according to the final discharge diagnosis. This therapy included diuretics or vasodilators in patients with heart failure, anticoagulants in patients with pulmonary embolism, and inhaled bronchodilators or systemic corticosteroids in patients with an exacerbation of obstructive pulmonary disease. All end points were assessed in a blinded fashion by physicians who were not involved in patient care, with the use of all medical records pertaining to each patient.
Statistical Analysis
The statistical analyses were performed with the use of the SPSS/PC software package (version 11.0, SPSS). A P value of less than 0.05 was considered to indicate statistical significance. All data were analyzed according to the intention-to-treat principle. Comparisons were made with the use of the t-test, the Mann–Whitney U test, Fisher's exact test, or the chi-square test, as appropriate. All hypothesis testing was two-tailed. The trial was designed to enroll 222 patients in each group. This number provided the study with a power of 80 percent to detect a reduction in the time to discharge from 10.0 to 8.0 days (20 percent) with the use of the diagnostic strategy guided by measurement of the B-type natriuretic peptide level. Assumptions included the use of a two-tailed test, a 5 percent level of significance, and a standard deviation of 7.5 days in both groups.
Results
A total of 452 patients were enrolled. The base-line characteristics were well matched between the study groups (Table 1Table 1
Base-Line Characteristics of the Patients.). The mean age was 71 years. In both groups, slightly more than 40 percent of the patients were women. The medical history included coronary artery disease in 50 percent of patients, hypertension in 52 percent, chronic obstructive pulmonary disease in 31 percent, any pulmonary disease in 50 percent, and diabetes in 23 percent.The median time from presentation at the emergency department to the initiation of the appropriate therapy according to the final discharge diagnosis was 90 minutes in the control group and 63 minutes in the B-type natriuretic peptide group (P=0.03) (Table 2Table 2
End Points.). The use of B-type natriuretic peptide levels significantly reduced the need for hospitalization and intensive care: 75 percent of patients in the B-type natriuretic peptide group were hospitalized, as compared with 85 percent of those in the control group (P=0.008), and 15 percent of patients in the B-type natriuretic peptide group required intensive care, as compared with 24 percent of those in the control group (P=0.01).There was a considerable range in the time to discharge, reflecting the variety of diseases responsible for acute dyspnea. As shown in Figure 1Figure 1
Cumulative Frequency Distribution Curve for the Time to Discharge of Patients in the B-Type Natriuretic Peptide Group as Compared with Those in the Control Group., the time to discharge was significantly shorter in the B-type natriuretic peptide group (median, 8.0 days) than in the control group (median, 11.0 days; P=0.001). This difference translated into a significant difference in the mean total cost of treatment: $7,264 in the control group, as compared with $5,410 in the B-type natriuretic peptide group (P=0.006). Twenty-one patients (9 percent) in the control group died in the hospital, as compared with 13 patients in the B-type natriuretic peptide group (6 percent, P=0.19).Heart failure was the final discharge diagnosis in 45 percent of patients in the B-type natriuretic peptide group and 51 percent of patients in the control group (P=0.2). Exacerbation of obstructive pulmonary disease was more commonly the cause of acute dyspnea in the B-type natriuretic peptide group than in the control group (23 percent vs. 11 percent, P=0.001). The treating physician indicated that two causes contributed to the acute dyspnea in 11 patients (5 percent) in the B-type natriuretic peptide group and in 10 patients (4 percent) in the control group (P=0.81).
Clinical 30-day follow-up data were available for all patients. The rates of readmission and mortality within 30 days after discharge were similarly low in the two groups (Table 2). The 30-day mortality rate was 10 percent in the B-type natriuretic peptide group and 12 percent in the control group. Among patients who were not initially admitted, rates of secondary admission were 5 percent in the B-type natriuretic peptide group (3 of 56 patients) and 9 percent in the control group (3 of 34 patients, P=0.67), and the respective 30-day mortality rates were 4 percent (2 deaths) and 3 percent (1 death) (P=1.00).
Discussion
This randomized, controlled trial examined the effect of the measurement of B-type natriuretic peptide levels in the emergency diagnosis of patients with acute dyspnea. The use of B-type natriuretic peptide levels in conjunction with other clinical information reduced the time to the initiation of the most appropriate therapy, the need for hospitalization and intensive care, the time to discharge, and the total cost of treatment. Given the morbidity associated with acute dyspnea and the cost associated with heart failure, chronic obstructive pulmonary disease, and other disorders that cause dyspnea,1-5,8,9,14 B-type natriuretic peptide testing is likely to be of value in the treatment of patients with acute dyspnea. The mean total cost of treatment in this study was similar to the expenditures in the United States. In 1997, an estimated $5,501 was spent for every hospital-discharge diagnosis of heart failure.3
B-type natriuretic peptide testing reduced the total cost of treatment by 26 percent. This finding is supported by a retrospective analysis of the cost effectiveness of the use of B-type natriuretic peptide levels in screening for left ventricular systolic dysfunction in the general population, which also showed a 26 percent reduction in cost.23
Our findings extend the conclusions of observational studies in which the use of the measurement of B-type natriuretic peptide levels was validated by comparison with a retrospectively adjudicated diagnosis of heart failure by independent cardiologists.3,6,7,9-14 In the largest of these studies — the Breathing Not Properly Multinational Study — B-type natriuretic peptide levels by themselves were more accurate than any historical or physical finding or laboratory value in identifying heart failure as the cause of dyspnea. The diagnostic accuracy of B-type natriuretic peptide at a cutoff value of 100 pg per milliliter was 83 percent, with a sensitivity of 90 percent and a specificity of 76 percent.6,7
In our study, exacerbation of obstructive pulmonary disease was more often the cause of acute dyspnea in the B-type natriuretic peptide group than in the control group. This finding corresponds well with a recent observation that exacerbation of chronic obstructive pulmonary disease frequently escapes recognition in the emergency department24 and is also in agreement with the high negative predictive value of the B-type natriuretic peptide level for the diagnosis of heart failure. B-type natriuretic peptide levels below 100 pg per milliliter in a patient with acute dyspnea make the diagnosis of heart failure very unlikely and apparently help clinicians focus on the most common alternative diagnosis. Obstructive pulmonary disease was present in one third of our patients and may well have gone unrecognized as the cause of acute dyspnea in a considerable number of patients in the control group. Our findings, along with those of other investigators, provide support for the inclusion of the measurement of natriuretic peptides in the recent European guidelines for the diagnosis of heart failure.5
A particular strength of our study is that the study population was highly representative of the elderly population of patients with heart failure in clinical practice.1-3 The mean age was 71 years, nearly half the patients were women, and coexisting conditions were common. The rapid and accurate differentiation of heart failure from other causes of acute dyspnea in such patients is often difficult, although essential for cost-effective management. The symptoms and signs of heart failure are neither sensitive nor specific and considerably overlap those of pulmonary disease.4-7,13 The approach to the emergency diagnosis of acute dyspnea has been fundamentally unchanged for decades and has been complemented by electrocardiography, chest radiography, and echocardiography for the assessment of left ventricular function. Unfortunately, these methods have important limitations.25-27
The clinical experience with B-type natriuretic peptide testing is limited. Our interpretation of the test results was based on the data available when the study protocol was devised. Further studies should help to optimize the use of B-type natriuretic peptide measurements in clinical practice. The use of normal values corrected for age and sex may represent a clinically significant advance, since the levels of B-type natriuretic peptide increase with age and are higher in women than in men.28 Moreover, a heart-failure diagnosis nomogram has been developed.8 In patients with severe renal disease, B-type natriuretic peptide levels are increased. The mean B-type natriuretic peptide level in patients with a noncardiac cause of dyspnea and an estimated glomerular filtration rate of less than 60 ml per minute per 1.73 m2 of body-surface area was nearly 300 pg per milliliter in the Breathing Not Properly Multinational Study.29 Therefore, higher cutoff values need to be identified for this important patient population.
In conclusion, we found that when used in conjunction with other clinical information, rapid measurement of B-type natriuretic peptide levels in the emergency department improves the care of patients with acute dyspnea and thereby reduces the time to discharge and the total cost of treatment.
Supported by research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the Novartis Foundation, the Krokus Foundation, and the University of Basel (to Dr. Mueller). Diagnostic devices and reagents (Triage) were provided by Biosite, San Diego, Calif.
We are indebted to the emergency department staff at University Hospital Basel for their valuable efforts, to all participating patients, and to Drs. Barbara Frana, Daniel Rodriguez, and Bruno Schurter for their help with data management.
Source Information
From the Department of Internal Medicine, Medical Division A (C.M., K.L.-K., A.P.P.), the Department of Laboratory Medicine (A.S.), the Emergency Department (B.M.), the Institute for Social and Preventive Medicine (C.S.), and the Division of Cardiology (P.B., M.P.), University of Basel, University Hospital, Basel, Switzerland.
Address reprint requests to Dr. Mueller at Medizinische Klinik A, Universitätsklinik, Petersgraben 4, CH-4031 Basel, Switzerland, or at chmueller@uhbs.ch.
- References
References
1
McCullough PA ,Philbin EF ,Spertus JA , et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002;39:60-69
CrossRef | Web of Science | Medline2
Redfield MM . Heart failure -- an epidemic of uncertain proportions. N Engl J Med 2002;347:1442-1444
Full Text | Web of Science | Medline3
Heart disease and stroke statistics — 2003 update. Dallas: American Heart Association, 2002.
4
Hunt SA ,Baker DW ,Chin MH , et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996-3007
CrossRef | Web of Science | Medline5
Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology
CrossRef | Web of Science | Medline6
Maisel AS ,Krishnaswamy P ,Nowak RM , et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167
Full Text | Web of Science | Medline7
McCullough PA ,Nowak RM ,McCord J , et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;106:416-422
CrossRef | Web of Science | Medline8
Bales AC ,Sorrentino MJ . Causes of congestive heart failure: prompt diagnosis may affect prognosis. Postgrad Med 1997;101:44-9, 54
CrossRef | Web of Science | Medline9
Wuerz RC ,Meador SA . Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 1992;21:669-674
CrossRef | Web of Science | Medline10
Morrison LK ,Harrison A ,Krishnaswamy P ,Kazanegra R ,Clopton P ,Maisel A . Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202-209
CrossRef | Web of Science | Medline11
Davis M ,Espiner E ,Richards G , et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 1994;343:440-444
CrossRef | Web of Science | Medline12
McDonagh TA ,Robb SD ,Murdoch DR , et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13
CrossRef | Web of Science | Medline13
Dao Q ,Krishnaswamy P ,Kazanegra R , et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-385
CrossRef | Web of Science | Medline14
Cabanes L ,Richaud-Thiriez B ,Fulla Y , et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001;120:2047-2050
CrossRef | Web of Science | Medline15
Yasue H ,Yoshimura M ,Sumida H , et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203
Web of Science | Medline16
Hama N ,Itoh H ,Shirakami G , et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995;92:1558-1564
Web of Science | Medline17
Wiese S ,Breyer T ,Dragu A , et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 2000;102:3074-3079
Web of Science | Medline18
Cheng V ,Kazanegra R ,Garcia A , et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-391
CrossRef | Web of Science | Medline19
Koglin J ,Pehlivanli S ,Schwaiblmair M ,Vogeser M ,Cremer P ,von Scheidt W . Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-1941
CrossRef | Web of Science | Medline20
Mueller C ,Buser P . B-type natriuretic peptide (BNP): can it improve our management of patients with congestive heart failure? Swiss Med Wkly 2002;132:618-622
Web of Science | Medline21
Weinstein MC ,Siegel JE ,Gold MR ,Kamlet MS ,Russell LB . Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-1258
CrossRef | Web of Science | Medline22
Siegel JE ,Weinstein MC ,Russell LB ,Gold MR . Recommendations for reporting cost-effectiveness analysis. JAMA 1996;276:1339-1341
CrossRef | Web of Science | Medline23
Nielsen OW ,McDonagh TA ,Robb SD ,Dargie HJ . Retrospective analysis of the cost-effectiveness of using plasma natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003;41:113-120
CrossRef | Web of Science | Medline24
Incalzi RA ,Fuso L ,Serra M , et al. Exacerbated chronic obstructive pulmonary disease: a frequently unrecognized condition. J Intern Med 2002;252:48-55
CrossRef | Web of Science | Medline25
Rihal CS ,Davis KB ,Kennedy JW ,Gersh BJ . The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. Am J Cardiol 1995;75:220-223
CrossRef | Web of Science | Medline26
Gillespie ND ,McNeill G ,Pringle T ,Ogston S ,Struthers AD ,Pringle SD . Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea. BMJ 1997;314:936-940
CrossRef | Web of Science | Medline27
Zile MR ,Gaasch WH ,Carroll JD , et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001;104:779-782
CrossRef | Web of Science | Medline28
Redfield MM ,Rodeheffer RJ ,Jacobsen SJ ,Mahoney DW ,Bailey KR ,Burnett JC Jr . Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-982
CrossRef | Web of Science | Medline29
McCullough PA ,Duc P ,Omland T , et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-579
CrossRef | Web of Science | Medline
- Citing Articles (288)
Citing Articles
1
A. Maisel, S.-X. Neath, J. Landsberg, C. Mueller, R. M. Nowak, W. F. Peacock, P. Ponikowski, M. Mockel, C. Hogan, A. H. B. Wu, M. Richards, P. Clopton, G. S. Filippatos, S. Di Somma, I. Anand, L. L. Ng, L. B. Daniels, R. H. Christenson, M. Potocki, J. McCord, G. Terracciano, O. Hartmann, A. Bergmann, N. G. Morgenthaler, S. D. Anker. (2012) Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. European Journal of Heart Failure
CrossRef2
Adonis Saremi, Dipika Gopal, Alan S Maisel. (2012) Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure. Expert Review of Cardiovascular Therapy 10:2, 191-203
CrossRef3
A. Luchner, M. Mockel, E. Spanuth, J. Mocks, D. Peetz, H. Baum, C. Spes, C. E. Wrede, J. Vollert, R. Muller, H. Katus, E. Giannitsis. (2012) N-terminal pro brain natriuretic peptide in the management of patients in the medical emergency department (PROMPT): correlation with disease severity, utilization of hospital resources, and prognosis in a large, prospective, randomized multicentre trial. European Journal of Heart Failure
CrossRef4
Damien Gruson, Jean-Marie Ketelslegers, Franck Verschuren, Frédéric Thys. (2011) Head-to-head comparison of the prohormone proBNP1–108 with BNP and Nt-proBNP in patients admitted to emergency department. Clinical Biochemistry
CrossRef5
David J. Whellan, Christopher J. Droogan, James Fitzpatrick, Suzanne Adams, Melissa M. Mccarey, Jocelyn Andrel, Paul Mather, Sharon Rubin, Raphael Bonita, Scott Keith. (2011) Change in Intrathoracic Impedance Measures During Acute Decompensated Heart Failure Admission: Results from the Diagnostic Data for Discharge in Heart Failure Patients (3D-HF) Pilot Study. Journal of Cardiac Failure
CrossRef6
Timothy B. Jang, Chandra Aubin, Rosanne Naunheim, Lawrence M. Lewis, Amy H. Kaji. (2011) The predictive value of physical examination findings in patients with suspected acute heart failure syndrome. Internal and Emergency Medicine
CrossRef7
N. Arenja, T. Reichlin, B. Drexler, S. Oshima, K. Denhaerynck, P. Haaf, M. Potocki, T. Breidthardt, M. Noveanu, C. Stelzig, C. Heinisch, R. Twerenbold, M. Reiter, T. Socrates, C. Mueller. (2011) Sensitive cardiac troponin in the diagnosis and risk stratification of acute heart failure. Journal of Internal Medicineno-no
CrossRef8
Christopher R. Carpenter, Samuel M. Keim, Andrew Worster, Peter Rosen. (2011) Brain Natriuretic Peptide in the Evaluation of Emergency Department Dyspnea: Is There a Role?. The Journal of Emergency Medicine
CrossRef9
M. Calderón Moreno, A.I. Castuera Gil, F.J. de Castro Martínez, E. Gargallo García. (2011) Insuficiencia cardiaca aguda. Medicine - Programa de Formación Médica Continuada Acreditado 10:88, 5932-5939
CrossRef10
Affan Irfan, Philip Haaf, Julia Meissner, Raphael Twerenbold, Miriam Reiter, Tobias Reichlin, Nora Schaub, Anina Zbinden, Corinna Heinisch, Beatrice Drexler, Katrin Winkler, Christian Mueller. (2011) Systolic blood pressure at Emergency Department presentation and 1-year mortality in acute chest pain patients. European Journal of Internal Medicine 22:5, 495-500
CrossRef11
John J. Atherton, Christopher S. Hayward, Wan Azman Wan Ahmad, Bernard Kwok, Jesus Jorge, Adrian F. Hernandez, Li Liang, Robb D. Kociol, Henry Krum. (2011) Patient Characteristics From a Regional Multicenter Database of Acute Decompensated Heart Failure in Asia Pacific (ADHERE International–Asia Pacific). Journal of Cardiac Failure
CrossRef12
Bo Hee Maeng, Jeongyeon Choi, Young Seung Sa, Jae Ho Shin, Yong Hwan Kim. (2011) Functional expression of recombinant anti-BNP scFv in methylotrophic yeast Pichia pastoris and application as a recognition molecule in electrochemical sensors. World Journal of Microbiology and Biotechnology
CrossRef13
Ludovic Trinquart, Patrick Ray, Bruno Riou, Antonio Teixeira. (2011) Natriuretic peptide testing in EDs for managing acute dyspnea: a meta-analysis. The American Journal of Emergency Medicine 29:7, 757-767
CrossRef14
W. Frank Peacock, Richard Nowak, Robert Christenson, Salvatore DiSomma, Sean Xavier Neath, Oliver Hartmann, Christian Mueller, Piotr Ponikowski, Martin Möckel, Christopher Hogan, Alan H. B. Wu, Mark Richards, Gerasimos S. Filippatos, Inder Anand, Leong L. Ng, Lori B. Daniels, Nils Morgenthaler, Stefan D. Anker, Alan S. Maisel. (2011) Short-term Mortality Risk in Emergency Department Acute Heart Failure. Academic Emergency Medicine 18:9, 947-958
CrossRef15
Philip Haaf, Cathrin Balmelli, Tobias Reichlin, Raphael Twerenbold, Miriam Reiter, Julia Meissner, Nora Schaub, Claudia Stelzig, Michael Freese, Patricia Paniz, Christophe Meune, Beatrice Drexler, Heike Freidank, Katrin Winkler, Willibald Hochholzer, Christian Mueller. (2011) N-terminal Pro B-type Natriuretic Peptide in the Early Evaluation of Suspected Acute Myocardial Infarction. The American Journal of Medicine 124:8, 731-739
CrossRef16
R. Pfister, C.A. Schneider. (2011) Diabetes mellitus und Herzinsuffizienz. Der Diabetologe 7:4, 247-253
CrossRef17
Kent Lewandrowski, James G. Flood, Leonard Tochka, Elizabeth Lee-Lewandrowski. (2011) Implementation of a Point-of-Care Satellite Laboratory (Kiosk) in the Emergency Department of an Academic Medical Center. Point of Care: The Journal of Near-Patient Testing & Technology 10:2, 93-97
CrossRef18
Bo Hee Maeng, Dong Hyun Nam, Yong Hwan Kim. (2011) Coexpression of molecular chaperones to enhance functional expression of anti-BNP scFv in the cytoplasm of Escherichia coli for the detection of B-type natriuretic peptide. World Journal of Microbiology and Biotechnology 27:6, 1391-1398
CrossRef19
Patrick Ray. (2011) Intérêt et limites des biomarqueurs en médecine d’urgence. Le Praticien en Anesthésie Réanimation 15:3, 154-164
CrossRef20
Richard W. Troughton, Lynley K. Lewis, Timothy G. Yandle, Christopher J. Pemberton, M. Gary Nicholls. (2011) B-type natriuretic peptides: Looking to the future. Annals of Medicine 43:3, 188-197
CrossRef21
Philip Haaf, Tobias Reichlin, Nils Corson, Raphael Twerenbold, Miriam Reiter, Stephan Steuer, Stefano Bassetti, Katrin Winkler, Claudia Stelzig, Corinna Heinisch, Beatrice Drexler, Heike Freidank, Christian Mueller. (2011) B-type Natriuretic Peptide in the Early Diagnosis and Risk Stratification of Acute Chest Pain. The American Journal of Medicine 124:5, 444-452
CrossRef22
Jonathan G. Howlett. (2011) Acute Heart Failure: Lessons Learned So Far. Canadian Journal of Cardiology 27:3, 284-295
CrossRef23
Sergio Manzano-Fernández, James L. Januzzi, Miguel Boronat García, Juan C. Bonaque-González, Carmen Muñoz-Esparza, María D. Albaladejo-Otón, Francisco J. Pastor-Pérez, Patricia Pastor, Mariano Valdés, Domingo A. Pascual-Figal. (2011) Valor pronóstico comparativo del pro-péptido natriurético tipo B aminoterminal urinario en pacientes con insuficiencia cardiaca aguda descompensada. Revista Española de Cardiología 64:5, 365-372
CrossRef24
P. Ray, C. Chenevier-Gobeaux, Y. -E. Claessens. (2011) Peptides natriurétiques, biomarqueurs de l’insuffisance cardiaque aux urgences. Annales françaises de médecine d'urgence 1:3, 200-205
CrossRef25
Ali Ahmed. (2011) Chronic Heart Failure in Older Adults. Medical Clinics of North America 95:3, 439-461
CrossRef26
Logan Stuckey, David Ward, Paul Negus. (2011) Correlation Between Point-of-Care and Laboratory-Analyzed B-Type Natriuretic Peptide in Adult Patients Presenting to Nambour Hospital Emergency Department With Shortness of Breath. Point of Care: The Journal of Near-Patient Testing & Technology 10:1, 25-27
CrossRef27
Stefan Toggweiler, Oliver Borst, Frank Enseleit, Matthias Hermann, Frank Ruschitzka, Thomas F. Lüscher, Georg Noll. (2011) NT-proBNP Provides Incremental Prognostic Information in Cardiac Outpatients With and Without Echocardiographic Findings. Clinical Cardiology 34:3, 183-188
CrossRef28
K. Thygesen, J. Mair, C. Mueller, K. Huber, M. Weber, M. Plebani, Y. Hasin, L. M. Biasucci, E. Giannitsis, B. Lindahl, W. Koenig, M. Tubaro, P. Collinson, H. Katus, M. Galvani, P. Venge, J. S. Alpert, C. Hamm, A. S. Jaffe. (2011) Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. European Heart Journal
CrossRef29
M. Noveanu, H. Pargger, T. Breidthardt, T. Reichlin, C. Schindler, A. Heise, R. Schoenenberger, P. Manndorff, M. Siegemund, A. Mebazaa, S. Marsch, C. Mueller. (2011) Use of B-type natriuretic peptide in the management of hypoxaemic respiratory failure. European Journal of Heart Failure 13:2, 154-162
CrossRef30
Emilie Dubois, Marie Fertin, Justine Burdese, Philippe Amouyel, Christophe Bauters, Florence Pinet. (2011) Cardiovascular proteomics: Translational studies to develop novel biomarkers in heart failure and left ventricular remodeling. PROTEOMICS - Clinical Applications 5:1-2, 57-66
CrossRef31
Kosaku Komiya, Hiroshi Ishii, Shinji Teramoto, Osamu Takahashi, Nobuoki Eshima, Ou Yamaguchi, Noriyuki Ebi, Junji Murakami, Hidehiko Yamamoto, Jun-ichi Kadota. (2011) Diagnostic utility of C-reactive Protein combined with brain natriuretic peptide in acute pulmonary edema: a cross sectional study. Respiratory Research 12:1, 83
CrossRef32
Cathrin Balmelli, Beatrice Drexler, Christian Mueller. (2011) Utile or futile: biomarkers in the ICU. Critical Care 15:2, 131
CrossRef33
Bei Cai, Lanlan Wang, Jin Liu, Yingkang Shi, Yingqiang Guo. (2011) N-terminal pro-Brain natriuretic peptide as a useful biomarker for monitoring prognosis in patients with cardiac valve replacement. Journal of Clinical Laboratory Analysis 25:3, 149-155
CrossRef34
Alan S. Maisel, Kazuwa Nakao, Piotr Ponikowski, W. Frank Peacock, Michihiro Yoshimura, Toru Suzuki, Takayoshi Tsutamoto, Gerasimos S. Filippatos, Yoshihiko Saito, Yoshihiko Seino, Naoto Minamino, Yasunobu Hirata, Masashi Mukoyama, Toshio Nishikimi, Ryozo Nagai. (2011) Japanese-Western Consensus Meeting on Biomarkers. International Heart Journal 52:5, 253-265
CrossRef35
Emanuel Burri, Mihael Potocki, Beatrice Drexler, Philipp Schuetz, Alexandre Mebazaa, Ulrike Ahlfeld, Catharina Balmelli, Corinna Heinisch, Markus Noveanu, Tobias Breidthardt, Nora Schaub, Tobias Reichlin, Christian Mueller. (2011) Value of arterial blood gas analysis in patients with acute dyspnea: an observational study. Critical Care 15:3, R145
CrossRef36
W. Frank Peacock, Ileana L. Piña. (2011) Primary Role of B-Type Natriuretic Peptide Across the Clinical Spectrum: From Emergency Medicine to Transitional Care and Beyond Into the Community. Congestive Heart Failure 17:1, 8-13
CrossRef37
Massimo de Cal, Mikko Haapio, Dinna N. Cruz, Paolo Lentini, Andrew A. House, Ilona Bobek, Grazia M. Virzì, Valentina Corradi, Flavio Basso, Pasquale Piccinni, Angela D'Angelo, Jamie W. Chang, Mitchell H. Rosner, Claudio Ronco. (2011) B-Type Natriuretic Peptide in the Critically Ill with Acute Kidney Injury. International Journal of Nephrology 2011, 1-6
CrossRef38
Ami N. Shah, Savina Nodari, Mihai Gheorghiade. (2011) Biomarkers in Acute Heart Failure Syndromes – Are They Fulfilling Their Promise. Cardiology 120:1, 19-21
CrossRef39
B. Drexler, C. Mueller. (2010) Natriuretic peptide-guided management by the general practitioner: how to interpret the SIGNAL. European Journal of Heart Failure 12:12, 1265-1267
CrossRef40
H. Persson, H. Erntell, B. Eriksson, G. Johansson, K. Swedberg, U. Dahlstrom. (2010) Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure - SIGNAL-HF (Swedish Intervention study - Guidelines and NT-proBNP AnaLysis in Heart Failure). European Journal of Heart Failure 12:12, 1300-1308
CrossRef41
K Kataoka, Y Nannya, H Iwata, S Seo, K Kumano, T Takahashi, R Nagai, M Kurokawa. (2010) Plasma brain natriuretic peptide is associated with hepatic veno-occlusive disease and early mortality after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 45:11, 1631-1637
CrossRef42
T. Socrates, C. DeFilippi, T. Reichlin, R. Twerenbold, T. Breidhardt, M. Noveanu, M. Potocki, M. Reiter, N. Arenja, C. Heinisch, J. Meissner, C. Jaeger, R. Christenson, C. Mueller. (2010) Interleukin family member ST2 and mortality in acute dyspnoea. Journal of Internal Medicine 268:5, 493-500
CrossRef43
D. Staub, T. Zeller, D. Trenk, C. Maushart, H. Uthoff, T. Breidthardt, T. Klima, M. Aschwanden, T. Socrates, N. Arenja, R. Twerenbold, A. Rastan, S. Sixt, A.L. Jacob, K.A. Jaeger, C. Mueller. (2010) Use of B-Type Natriuretic Peptide to Predict Blood Pressure Improvement after Percutaneous Revascularisation for Renal Artery Stenosis. European Journal of Vascular and Endovascular Surgery 40:5, 599-607
CrossRef44
Corrine Y. Jurgens, Kathleen M. Shurpin, Kellie A. Gumersell. (2010) Challenges and Strategies for Heart Failure Symptom Management in Older Adults. Journal of Gerontological Nursing
CrossRef45
John R. Teerlink. 2010. Treatment of Acutely Decompensated Heart Failure. , 327-356.
CrossRef46
Constantin Goritsas, Magdalini Fasoulaki, Nikolaos P. Paissios, Emilia Giakoumaki, Yannis Alamanos, Nikolaos I. Nikolaou. (2010) Brain natriuretic peptide plasma levels as a marker of prognosis in patients with community-acquired infection. European Journal of Emergency Medicine 17:5, 293-295
CrossRef47
Willibald Hochholzer, David A. Morrow, Robert P. Giugliano. (2010) Novel biomarkers in cardiovascular disease: Update 2010. American Heart Journal 160:4, 583-594
CrossRef48
C. Lüers, A. Schmidt, R. Wachter, F. Fritzsche, A. Sutcliffe, S. Kleta, A. Zapf, G. Hagenah, L. Binder, B. Maisch, B. Pieske. (2010) Serial NT-proBNP measurements for risk stratification of patients with decompensated heart failure. Herz 35:7, 488-496
CrossRef49
Rakesh S. Engineer, Justin L. Benoit, Caitlin W. Hicks, Sunny J. Kolattukudy, Daniel Burkhoff, W. Frank Peacock. (2010) Hemodynamic changes as a diagnostic tool in acute heart failure—a pilot study. The American Journal of Emergency Medicine
CrossRef50
William C. Mabie. 2010. Pulmonary Edema. , 348-357.
CrossRef51
Kristin Pothier, Mark Kirtland, Sonia Gupta. (2010) Has Point-of-Care Come of Age?. Point of Care: The Journal of Near-Patient Testing & Technology 9:3, 147-150
CrossRef52
Claus Lüers, Gerrit Hagenah, Rolf Wachter, Sibylle Kleta, Jens Schaumberg, Sebastian Riedel, Lutz Binder, Klaus Jung, Albrecht Schmidt, Burkert Pieske. (2010) Bedeutung der Surfactant-Proteine B und D in der Differentialdiagnostik der akuten Dyspnoe. Medizinische Klinik 105:9, 611-618
CrossRef53
Juha S. Perkiömäki, Sari Hämekoski, M. Juhani Junttila, Vesa Jokinen, Jari Tapanainen, Heikki V. Huikuri. (2010) Predictors of Long-Term Risk for Heart Failure Hospitalization after Acute Myocardial Infarction. Annals of Noninvasive Electrocardiology 15:3, 250-258
CrossRef54
Pam R. Taub, Paulette Gabbai-Saldate, Alan Maisel. (2010) Biomarkers of Heart Failure. Congestive Heart Failure 16, S19-S24
CrossRef55
W. Frank Peacock, Eugene Braunwald, William Abraham, Nancy Albert, John Burnett, Rob Christenson, Sean Collins, Deborah Diercks, Greg Fonarow, Judd Hollander, Art Kellerman, Mihai Gheorghiade, Doug Kirk, Phil Levy, Alan Maisel, Barry M. Massie, Christopher O'Connor, Peter Pang, Monica Shah, George Sopko, Lynne Stevenson, Alan Storrow, John Teerlink. (2010) National Heart, Lung, and Blood Institute Working Group on Emergency Department Management of Acute Heart Failure. Journal of the American College of Cardiology 56:5, 343-351
CrossRef56
Kimberly D Tran, Niraj V Parekh, Alan S Maisel. (2010) Natriuretic peptides in heart failure. Therapy 7:4, 355-365
CrossRef57
Jun R. Chiong, Geoffrey T. Jao, Kirkwood F. Adams. (2010) Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure. Heart Failure Reviews 15:4, 275-291
CrossRef58
Tujana Boldanova, Markus Noveanu, Tobias Breidthardt, Mihael Potocki, Tobias Reichlin, Anne Taegtmeyer, Michael Christ, Kirsten Laule, Claudia Stelzig, Christian Mueller. (2010) Impact of history of heart failure on diagnostic and prognostic value of BNP: Results from the B-type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) Study. International Journal of Cardiology 142:3, 265-272
CrossRef59
Geoffrey de Couto, Maral Ouzounian, Peter P. Liu. (2010) Early detection of myocardial dysfunction and heart failure. Nature Reviews Cardiology 7:6, 334-344
CrossRef60
Meredith O. Cruz, Joan Briller, Judith U. Hibbard. (2010) Update on Peripartum Cardiomyopathy. Obstetrics and Gynecology Clinics of North America 37:2, 283-303
CrossRef61
Alan Maisel, Christian Mueller, Richard Nowak, W. Frank Peacock, Judd W. Landsberg, Piotr Ponikowski, Martin Mockel, Christopher Hogan, Alan H.B. Wu, Mark Richards, Paul Clopton, Gerasimos S. Filippatos, Salvatore Di Somma, Inder Anand, Leong Ng, Lori B. Daniels, Sean-Xavier Neath, Robert Christenson, Mihael Potocki, James McCord, Garret Terracciano, Dimitrios Kremastinos, Oliver Hartmann, Stephan von Haehling, Andreas Bergmann, Nils G. Morgenthaler, Stefan D. Anker. (2010) Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea. Journal of the American College of Cardiology 55:19, 2062-2076
CrossRef62
Michela Salvatici, Daniela Cardinale, Lorenzo Spaggiari, Fabrizio Veglia, Calogero Claudio Tedesco, Piergiorgio Solli, Carlo Maria Cipolla, Laura Zorzino, Rita Passerini, Daniela Riggio, Maria Cristina Cassatella, Maria Teresa Sandri. (2010) Atrial fibrillation after thoracic surgery for lung cancer: use of a single cut-off value of N-terminal pro-B type natriuretic peptide to identify patients at risk. Biomarkers 15:3, 259-265
CrossRef63
Christopher Moriates, Alan Maisel. (2010) The Utility of Biomarkers in Sorting Out the Complex Patient. The American Journal of Medicine 123:5, 393-399
CrossRef64
Hun-Jun Park, Sang Hong Baek, Sung Won Jang, Dong-Bin Kim, Dong Il Shin, Woo-Seung Shin, Pum Joon Kim, Hae-Bin Jung, Hae-Ok Jung, Ki-Bae Seung, Kyu Bo Choi. (2010) Direct comparison of B-type natriuretic peptide and N-terminal pro-BNP for assessment of cardiac function in a large population of symptomatic patients. International Journal of Cardiology 140:3, 336-343
CrossRef65
Gökmen Gemici, Ali Kemal Kalkan, Muzaffer Degertekin, Ertan Demirtas. (2010) Artifact mimicking non-sustained polymorphic ventricular tachycardia in a patient with recent myocardial infarction. Central European Journal of Medicine 5:2, 154-155
CrossRef66
Canan Topçuoğlu, Fatma Meriç Yılmaz, Deniz Şahin, Sinan Aydoğdu, Gülsen Yılmaz, Gülsevim Saydam, Doğan Yücel. (2010) Total-and lipid-associated sialic acid in serum and thrombocytes in patients with chronic heart failure. Clinical Biochemistry 43:4-5, 447-449
CrossRef67
Andrea Bellone, Massimiliano Etteri, Marco Vettorello, Vittorio Berruti, Carlo Maino, Massimo Mariani, Dante Clerici, Italo Nessi, Giancarlo Gini, Anna Natalizi, Pietro Brunati. (2010) The effects of continuous positive airway pressure on plasma brain natriuretic peptide concentrations in patients presenting with acute cardiogenic pulmonary edema with preserved left ventricular systolic function. The American Journal of Emergency Medicine 28:2, 230-234
CrossRef68
2010. General Preoperative Considerations and Preparation of the Patient for Surgery. , 129-171.
CrossRef69
M. Potocki, T. Breidthardt, T. Reichlin, S. Hartwiger, N. G. Morgenthaler, A. Bergmann, M. Noveanu, H. Freidank, A. B. Taegtmeyer, K. Wetzel, T. Boldanova, C. Stelzig, R. Bingisser, M. Christ, C. Mueller. (2010) Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic ⨠peptide in the diagnosis of heart failure. Journal of Internal Medicine 267:1, 119-129
CrossRef70
Thomas Reinhold, Anne Berghöfer, Stefan N. Willich. (2010) Sind Biomarker ihr Geld wert?. Herz 35:1, 1-10
CrossRef71
Anju Bhardwaj, James L. Januzzi. (2009) Natriuretic Peptide-Guided Management of Acutely Destabilized Heart Failure. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 8:4, 146-150
CrossRef72
Dominik Berliner, Christiane E. Angermann, Georg Ertl, Stefan Störk. (2009) Biomarkers in Heart Failure – Better than History or Echocardiography?. Herz 34:8, 581-588
CrossRef73
Armen Kocharian, Reza Shabanian, Mitra Rahimzadeh, Abdolrazagh Kiani, Ahmad Hosseini, Keyhan Sayadpour Zanjani, Giv Heidari-Bateni, Nasrollah Hosseini-Navid. (2009) N-terminal Pro-B-type Natriuretic Peptide and Ventricular Dysfunction in Children and Adolescents. Cardiology in the Young 19:06, 580
CrossRef74
Mitja Lainscak, Markus S. Anker, Stephan Haehling, Stefan D. Anker. (2009) Biomarkers for Chronic Heart Failure. Herz 34:8, 589-593
CrossRef75
Mona Salem, Soha El Behery, Amira Adly, Dina Khalil, Eman El Hadidi. (2009) Early predictors of myocardial disease in children and adolescents with type 1 diabetes mellitus. Pediatric Diabetes 10:8, 513-521
CrossRef76
Tansu Karaahmet, Fatih Yilmaz, Kursat Tigen, Bulent Mutlu, Cihan Cevik, Yelda Basaran. (2009) Diagnostic Utility of Plasma N-Terminal Pro-B-Type Natriuretic Peptide and C-Reactive Protein Levels in Differential Diagnosis of Pericardial Constriction and Restrictive Cardiomyopathy. Congestive Heart Failure 15:6, 265-270
CrossRef77
Daniel Bolliger, Manfred D. Seeberger, Miodrag Filipovic. (2009) Pre-Operative Cardiac Risk Assessment in Noncardiac Surgery. Journal of the American College of Cardiology 54:17, 1607-1608
CrossRef78
John G.T. Augoustides, Hynek Riha. (2009) Recent Progress in Heart Failure Treatment and Heart Transplantation. Journal of Cardiothoracic and Vascular Anesthesia 23:5, 738-748
CrossRef79
Thenral Socrates, Nisha Arenja, Christian Mueller. (2009) B-Type Natriuretic Peptide in Children. Journal of the American College of Cardiology 54:15, 1476-1477
CrossRef80
Ragavendra R. Baliga, James B. Young. (2009) Editorial. Heart Failure Clinics 5:4, ix-xii
CrossRef81
WH Wilson Tang. (2009) Biomarkers of risk stratification in congestive heart failure: North American view. Biomarkers in Medicine 3:5, 443-452
CrossRef82
Rajeev Garg, Avneet Singh, Azam Khaja, Alpert Martin, Kul Aggarwal. (2009) How Does Volume Status Affect BNP and Troponin Levels as Markers of Cardiovascular Status in Peritoneal Dialysis?. Congestive Heart Failure 15:5, 240-244
CrossRef83
Domenico Paparella, Pietro Giorgio Malvindi, Roberta Romito, Massimo Iacoviello, Giuseppe Visicchio, Francesca Di Serio, Stefano Favale, Luigi de Luca Tupputi Schinosa. (2009) BNP in mitral valve restrictive annuloplasty for ischemic mitral regurgitation. International Journal of Cardiology 137:1, 57-60
CrossRef84
Elizabeth Lee-Lewandrowski, Kent Lewandrowski. (2009) Perspectives on Cost and Outcomes for Point-of-Care Testing. Clinics in Laboratory Medicine 29:3, 479-489
CrossRef85
Kent Lewandrowski. (2009) Point-of-Care Testing for Cardiac Markers in Acute Coronary Syndromes and Heart Failure. Clinics in Laboratory Medicine 29:3, 561-571
CrossRef86
Reichlin, Tobias, Hochholzer, Willibald, Bassetti, Stefano, Steuer, Stephan, Stelzig, Claudia, Hartwiger, Sabine, Biedert, Stefan, Schaub, Nora, Buerge, Christine, Potocki, Mihael, Noveanu, Markus, Breidthardt, Tobias, Twerenbold, Raphael, Winkler, Katrin, Bingisser, Roland, Mueller, Christian, . (2009) Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assays. New England Journal of Medicine 361:9, 858-867
Full Text87
A. Oscarsson, M. Fredrikson, M. Sorliden, S. Anskar, C. Eintrei. (2009) N-terminal fragment of pro-B-type natriuretic peptide is a predictor of cardiac events in high-risk patients undergoing acute hip fracture surgery. British Journal of Anaesthesia 103:2, 206-212
CrossRef88
Mihael Potocki, Johannes Mair, Michael Weber, Christian Hamm, Thilo Burkard, Renate Hiemetzberger, Klaus Peters, Nikolaus Jander, Thomas A. Cron, Niklaus Hess, Andreas Hoffmann, Helmut Gekeler, Christa Gohlke-Bärwolf, Peter Buser, Christian Mueller. (2009) Relation of N-Terminal Pro-B-Type Natriuretic Peptide to Symptoms, Severity, and Left Ventricular Remodeling in Patients With Organic Mitral Regurgitation. The American Journal of Cardiology 104:4, 559-564
CrossRef89
Tobias Breidthardt, Markus Noveanu, Sevgi Cayir, Martina Viglino, Kirsten Laule, Willibald Hochholzer, Tobias Reichlin, Mihael Potocki, Michael Christ, Christian Mueller. (2009) The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. International Journal of Cardiology 136:2, 193-199
CrossRef90
Daniel Staub, Daniel Jauslin, Heike Freidank, Anne Taegtmeyer, Tobias Breidthardt, Michael J. Zellweger, Jan Mueller-Brand, Michael Christ, Christian Mueller. (2009) Use of changes in B-type natriuretic peptides to detect ischemia in selected patients. International Journal of Cardiology 136:1, 40-46
CrossRef91
Christian Mueller. (2009) Cost-Effectiveness of B-Type Natriuretic Peptide in the Management of Dyspnea. Clinical Pulmonary Medicine 16:4, 199-201
CrossRef92
O. James Ekundayo, Virginia J. Howard, Monika M. Safford, Leslie A. McClure, Donna Arnett, Richard M. Allman, George Howard, Ali Ahmed. (2009) Value of Orthopnea, Paroxysmal Nocturnal Dyspnea, and Medications in Prospective Population Studies of Incident Heart Failure. The American Journal of Cardiology 104:2, 259-264
CrossRef93
Alain Cohen-Solal, Damien Logeart, Bidan Huang, Danlin Cai, Markku S. Nieminen, Alexandre Mebazaa. (2009) Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure. Journal of the American College of Cardiology 53:25, 2343-2348
CrossRef94
Michael Behnes, Martina Brueckmann, Parviz Ahmad-Nejad, Siegfried Lang, Christian Wolpert, Elif Elmas, Thorsten Kaelsch, Joachim Gruettner, Christel Weiβ, Martin Borggrefe, Michael Neumaier. (2009) Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. International Journal of Cardiology 135:2, 165-174
CrossRef95
Tobias Reichlin, Willibald Hochholzer, Claudia Stelzig, Kirsten Laule, Heike Freidank, Nils G. Morgenthaler, Andreas Bergmann, Mihael Potocki, Markus Noveanu, Tobias Breidthardt, Andreas Christ, Tujana Boldanova, Ramona Merki, Nora Schaub, Roland Bingisser, Michael Christ, Christian Mueller. (2009) Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction. Journal of the American College of Cardiology 54:1, 60-68
CrossRef96
Amandeep S. Dhaliwal, Anita Deswal, Allison Pritchett, David Aguilar, Biswajit Kar, Julianne Souchek, Biykem Bozkurt. (2009) Reduction in BNP Levels With Treatment of Decompensated Heart Failure and Future Clinical Events. Journal of Cardiac Failure 15:4, 293-299
CrossRef97
N. van der Burg-de Graauw, C.M. Cobbaert, C.J.F.M. Middelhoff, T.A. Bantje, C. van Guldener. (2009) The additive value of N-terminal pro-B-type natriuretic peptide testing at the emergency department in patients with acute dyspnoea. European Journal of Internal Medicine 20:3, 301-306
CrossRef98
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, e1-e90
CrossRef99
Mariell Jessup, William T. Abraham, Donald E. Casey, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Marvin A. Konstam, Donna M. Mancini, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, 1343-1382
CrossRef100
Christian Mueller, Micha T. Maeder, Andreas Christ, Tobias Reichlin, Daniel Staub, Markus Noveanu, Tobias Breidthardt, Mihael Potocki, Martin H. Brutsche. (2009) B-Type Natriuretic Peptides for the Evaluation of Exercise Intolerance. The American Journal of Medicine 122:3, 265-272
CrossRef101
Philippe Meyer, O. James Ekundayo, Chris Adamopoulos, Marjan Mujib, Inmaculada Aban, Michel White, Wilbert S. Aronow, Ali Ahmed. (2009) A Propensity-Matched Study of Elevated Jugular Venous Pressure and Outcomes in Chronic Heart Failure. The American Journal of Cardiology 103:6, 839-844
CrossRef102
Gaia Cattadori, Karlman Wasserman, Chiara Meloni, Saima Mustaq, Mauro Contini, Anna Apostolo, Daniele Andreini, Damiano Magrì, Susanna Sciomer, Fabrizio Veglia, Giovanni Berna, Giovanni Introcaso, Pietro Palermo, Cesare Fiorentini, Piergiuseppe Agostoni. (2009) Alveolar Membrane Conductance Decreases as BNP Increases During Exercise in Heart Failure. Rationale for BNP in the Evaluation of Dyspnea. Journal of Cardiac Failure 15:2, 136-144
CrossRef103
Mitja Lainscak, Stephan von Haehling, Stefan D. Anker. (2009) Natriuretic peptides and other biomarkers in chronic heart failure: From BNP, NT-proBNP, and MR-proANP to routine biochemical markers. International Journal of Cardiology 132:3, 303-311
CrossRef104
Armand Mekontso Dessap, Laurent Brochard. (2009) B-Type Natriuretic Peptide and Weaning From Mechanical Ventilation. Clinical Pulmonary Medicine 16:2, 89-94
CrossRef105
Jonathan G. Howlett, Robert S. McKelvie, J Malcolm O. Arnold, Jeannine Costigan, Paul Dorian, Anique Ducharme, Estrellita Estrella-Holder, Justin A. Ezekowitz, Nadia Giannetti, Haissam Haddad, George A. Heckman, Anthony M. Herd, Debra Isaac, Philip Jong, Simon Kouz, Peter Liu, Elizabeth Mann, Gordon W. Moe, Ross T. Tsuyuki, Heather J. Ross, Michel White. (2009) Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Canadian Journal of Cardiology 25:2, 85-105
CrossRef106
Mihai Gheorghiade, Peter S. Pang. (2009) Acute Heart Failure Syndromes. Journal of the American College of Cardiology 53:7, 557-573
CrossRef107
Richard W. Troughton, A. Mark Richards. (2009) B-Type Natriuretic Peptides and Echocardiographic Measures of Cardiac Structure and Function. JACC: Cardiovascular Imaging 2:2, 216-225
CrossRef108
Jean-Christophe Allo, Jean-Francois Vigneau, Jie Jiang, Roger Ranerison, Elie Caroline, Aurélie Dabreteau, Guillaume Der Sahakian, Franck Perruche, Jean-Francois Dhainaut, Fabrice Brunet, Yann-Erick Claessens. (2009) Appropriateness of diagnosis and orientation of 996 consecutive patients admitted in an emergency department with flow-based organization. European Journal of Emergency Medicine 16:1, 23-28
CrossRef109
Anna Marie Chang, Alan S. Maisel, Judd E. Hollander. (2009) Diagnosis of Heart Failure. Heart Failure Clinics 5:1, 25-35
CrossRef110
A.-B. Tonnel. 2009. Dyspnée. , 39-46.
CrossRef111
Alpesh Amin. (2008) Hospitalized patients with acute decompensated heart failure: Recognition, risk stratification, and treatment review. Journal of Hospital Medicine 3:S6, S16-S24
CrossRef112
Rungroj Krittayaphong, Thananya Boonyasirinant, Pairash Saiviroonporn, Suthipol Udompunturak. (2008) NT-proBNP levels in the evaluation of right ventricular dysfunction in patients with coronary artery disease and abnormal left ventricular wall motion: a magnetic resonance imaging study. Coronary Artery Disease 19:7, 481-487
CrossRef113
Felix Post, Ludwig S. Weilemann, Claudia-Martina Messow, Christoph Sinning, Thomas Münzel. (2008) B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients*. Critical Care Medicine 36:11, 3030-3037
CrossRef114
Jordi Ordonez-Llanos, Javier Merce-Muntanola, Miquel Santalo-Bel. (2008) Natriuretic peptide testing in emergency settings. Clinical Chemistry and Laboratory Medicine 46:11, 1543-1549
CrossRef115
Mark Flemmer, Hussein Rajab, Tracy Mathena, James Paulson, Susan Perkins, Thomas Whelan, Ritche Chiu, Peter A. McCullough. (2008) Blood B-Type Natriuretic Peptide and Dialysis: Present Assessment and Future Analyses. Southern Medical Journal 101:11, 1094-1100
CrossRef116
Christian Mueller. (2008) Risk stratification in acute decompensated heart failure: the role of cardiac troponin. Nature Clinical Practice Cardiovascular Medicine 5:11, 680-681
CrossRef117
Markus Noveanu, Mihael Potocki, Christian Mueller. (2008) Natriuretic peptides and their evolving clinical applications. Future Cardiology 4:6, 593-598
CrossRef118
Piotr Kubler, Ewa A. Jankowska, Jacek Majda, Krzysztof Reczuch, Waldemar Banasiak, Piotr Ponikowski. (2008) Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome. International Journal of Cardiology 129:3, 373-378
CrossRef119
Kevin Jiang, Kevin Shah, Lori Daniels, Alan S Maisel. (2008) Review on natriuretic peptides: where we are, where we are going. Expert Opinion on Medical Diagnostics 2:10, 1137-1153
CrossRef120
Johannes Steiner, Maya Guglin. (2008) BNP or NTproBNP? A clinician's perspective. International Journal of Cardiology 129:1, 5-14
CrossRef121
Daniel D. Correa de Sa, Horng H. Chen. (2008) The role of natriuretic peptides in heart failure. Current Heart Failure Reports 5:3, 177-184
CrossRef122
KYLE LIEPPMAN, LORI KRAMER-CLARK, JOSEPH D. TOBIAS. (2008) Plasma B-type natriuretic peptide monitoring to evaluate cardiovascular function prior to organ procurement in patients with brain death. Pediatric Anesthesia 18:9, 852-856
CrossRef123
Iwona Szadkowska, Jan Henryk Goch, Janusz Kawiński, Krzysztof Chiżyński. (2008) N-terminal Pro-brain Natriuretic Peptide in the Elderly with Myocardial Infarction. Clinical Cardiology 31:9, 443-447
CrossRef124
Shafiq U. Rehman, James L. Januzzi. (2008) Natriuretic Peptide Testing in Clinical Medicine. Cardiology in Review 16:5, 240-249
CrossRef125
Samo Zver, Vesna Zadnik, Peter Černelč, Mirta Koželj. (2008) Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. International Journal of Hematology 88:2, 227-236
CrossRef126
Ueli Studler, Martin Kretzschmar, Michael Christ, Tobias Breidthardt, Markus Noveanu, Andreas Schoetzau, André P. Perruchoud, Wolfgang Steinbrich, Christian Mueller. (2008) Accuracy of chest radiographs in the emergency diagnosis of heart failure. European Radiology 18:8, 1644-1652
CrossRef127
M. Christ-Crain, T. Breidthardt, D. Stolz, K. Zobrist, R. Bingisser, D. Miedinger, J. Leuppi, M. Tamm, B. Mueller, C. Mueller. (2008) Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. Journal of Internal Medicine 264:2, 166-176
CrossRef128
Alan S. Maisel, William F. Peacock, N. McMullin, Robert Jessie, Gregg C. Fonarow, Janet Wynne, Roger M. Mills. (2008) Timing of Immunoreactive B-Type Natriuretic Peptide Levels and Treatment Delay in Acute Decompensated Heart Failure. Journal of the American College of Cardiology 52:7, 534-540
CrossRef129
(2008) Symposium Abstracts. Clinical Chemistry and Laboratory Medicine 46:S1, S5-S169
CrossRef130
P. Ray, S. Delerme, P. Jourdain, C. Chenevier-Gobeaux. (2008) Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department. QJM 101:11, 831-843
CrossRef131
Nadia Aspromonte, Roberto Valle, William F. Peacock, Marc Vanderheyden, Alan Maisel. (2008) Inpatient Monitoring and Prognostic Importance of B-Type Natriuretic Peptide. Congestive Heart Failure 14, 30-34
CrossRef132
W. Frank Peacock, Christian Mueller, Salvatore DiSomma, Alan Maisel. (2008) Emergency Department Perspectives on B-Type Natriuretic Peptide Utility. Congestive Heart Failure 14, 17-20
CrossRef133
Salvatore DiSomma, Laura Magrini, Valerio Pittoni, Rossella Marino, W. Frank Peacock, Alan Maisel. (2008) Usefulness of Serial Assessment of Natriuretic Peptides in the Emergency Department for Patients With Acute Decompensated Heart Failure. Congestive Heart Failure 14, 21-24
CrossRef134
Christian Mueller. (2008) Cost-Effectiveness of B-Type Natriuretic Peptide Testing. Congestive Heart Failure 14, 35-37
CrossRef135
Joost H.W. Rutten, Ewout W. Steyerberg, Frans Boomsma, Jan L.C.M. van Saase, Jaap W. Deckers, Henk C. Hoogsteden, Jan Lindemans, Anton H. van den Meiracker. (2008) N-terminal pro–brain natriuretic peptide testing in the emergency department: Beneficial effects on hospitalization, costs, and outcome. American Heart Journal 156:1, 71-77
CrossRef136
Christian Mueller. (2008) Cost-Effectiveness of B-Type Natriuretic Peptide Testing. Congestive Heart Failure 14:4, 35-37
CrossRef137
Ali Ahmed, Linda Jones, Clare I. Hays. (2008) DEFEAT Heart Failure: Assessment and Management of Heart Failure in Nursing Homes Made Easy. Journal of the American Medical Directors Association 9:6, 383-389
CrossRef138
Jenny A. Doust, Jonathon C. Craig. (2008) Evaluating diagnostic tests—should the same methods apply?. American Heart Journal 156:1, 4-6
CrossRef139
W. Frank Peacock, Christian Mueller, Salvatore DiSomma, Alan Maisel. (2008) Emergency Department Perspectives on B-Type Natriuretic Peptide Utility. Congestive Heart Failure 14:4, 17-20
CrossRef140
Epaminondas Zakynthinos, Theodoros Kiropoulos, Konstantinos Gourgoulianis, Gerasimos Filippatos. (2008) Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases. Heart & Lung: The Journal of Acute and Critical Care 37:4, 275-285
CrossRef141
Nadia Aspromonte, Roberto Valle, William F. Peacock, Marc Vanderheyden, Alan Maisel. (2008) Inpatient Monitoring and Prognostic Importance of B-Type Natriuretic Peptide. Congestive Heart Failure 14:4, 30-34
CrossRef142
Salvatore DiSomma, Laura Magrini, Valerio Pittoni, Rossella Marino, W. Frank Peacock, Alan Maisel. (2008) Usefulness of Serial Assessment of Natriuretic Peptides in the Emergency Department for Patients With Acute Decompensated Heart Failure. Congestive Heart Failure 14:4, 21-24
CrossRef143
Micha T. Maeder, Christian Mueller, Matthias E. Pfisterer, Peter T. Buser, Hans P. Brunner-La Rocca. (2008) Use of B-type natriuretic peptide outside of the emergency department. International Journal of Cardiology 127:1, 5-16
CrossRef144
Kellan E. Ashley, John M. Galla, Stephen J. Nicholls. (2008) Brain Natriuretic Peptides as Biomarkers for Atherosclerosis. Preventive Cardiology 11:3, 172-176
CrossRef145
Andreas Synetos, Konstantinos Aznaouridis, Stamatios Lerakis. (2008) Brain Natriuretic Peptide in Cardiovascular Diseases. The American Journal of the Medical Sciences 335:6, 477-483
CrossRef146
Debra L Isaac. (2008) Biomarkers in heart failure management. Current Opinion in Internal Medicine 7:3, 226-232
CrossRef147
Jung-Ju Sir, Woo-Young Chung, Seok-Jae Hwang, Hyun-Jae Kang, Young-Seok Cho, Bon-Kwon Koo, In-Ho Chae, Dong-Ju Choi, Hyo-Soo Kim, Dae-Won Sohn, Cheol-Ho Kim, Byung-Hee Oh, Young-Bae Park, Yun-Shik Choi. (2008) N-terminal pro-B-type natriuretic peptide as a predictor of repeat coronary revascularization. International Journal of Cardiology 126:3, 322-332
CrossRef148
Braunwald, Eugene, . (2008) Biomarkers in Heart Failure. New England Journal of Medicine 358:20, 2148-2159
Full Text149
Peacock, W. Frank IV, De Marco, Teresa, Fonarow, Gregg C., Diercks, Deborah, Wynne, Janet, Apple, Fred S., Wu, Alan H.B.. (2008) Cardiac Troponin and Outcome in Acute Heart Failure. New England Journal of Medicine 358:20, 2117-2126
Full Text150
Fábio Vilas-Boas, Gilson Soares Feitosa, Milena B.P. Soares, Joel Alves Pinho-Filho, Thais Nascimento, Marcos M. Barojas, Marcus V.S. Andrade, Ricardo Ribeiro-dos-Santos, Edimar Bocchi. (2008) Invasive and Noninvasive Correlations of B-Type Natriuretic Peptide in Patients With Heart Failure Due to Chagas Cardiomyopathy. Congestive Heart Failure 14:3, 121-126
CrossRef151
Daniel D. Correa de Sa, Horng H. Chen. (2008) The role of natriuretic peptides in heart failure. Current Cardiology Reports 10:3, 182-189
CrossRef152
Michael Christ, Kirsten Laule, Theresia Klima, Willibald Hochholzer, Tobias Breidthardt, Andre P. Perruchoud, Christian Mueller. (2008) Multimarker strategy for risk prediction in patients presenting with acute dyspnea to the emergency department. International Journal of Cardiology 126:1, 73-78
CrossRef153
Evangelos Giannitsis, Hannsjörg Baum, Thomas Bertsch, Martin Juchum, Margit Müller-Bardorff, Bo Jørgensen, Agathe Böhmer, Martina Rebmann, Jürgen Schäffler, Michael Schwab, Rainer Zerback. (2008) Multicentre evaluation of a new point-of-care test for the determination of CK-MB in whole blood. Clinical Chemistry and Laboratory Medicine 46:5, 630-638
CrossRef154
Christian Mueller. (2008) Acute respiratory failure: back to the roots!. Intensive Care Medicine 34:5, 787-789
CrossRef155
Massimiliano Cantinotti, Aldo Clerico, Michele Murzi, Simona Vittorini, Michele Emdin. (2008) Clinical relevance of measurement of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in pediatric cardiology. Clinica Chimica Acta 390:1-2, 12-22
CrossRef156
Manuel Jiménez-Navarro, Juan Delgado Jiménez, Miguel Rivera Otero, Eulalia Roig Minguell, Javier Segovia Cubero, Luis Almenar Bonet, Manuel Anguita Sánchez, Antoni Bayés-Genís, María G. Crespo Leiro. (2008) Utilidad de los péptidos natriuréticos en la insuficiencia cardíaca. Medicina Clínica 130:15, 591-596
CrossRef157
W.H. Wilson Tang, Gary S. Francis, David A. Morrow, L. Kristin Newby, Christopher P. Cannon, Robert L. Jesse, Alan B. Storrow, Robert H. Christenson, Robert H. Christenson, Fred S. Apple, Christopher P. Cannon, Gary S. Francis, Robert L. Jesse, David A. Morrow, L. Kristin Newby, Alan B. Storrow, W. H. Wilson Tang, Alan H.B. Wu. (2008) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure. Clinical Biochemistry 41:4-5, 210-221
CrossRef158
J.W. Busse, D. Bassler, G.H. Guyatt. (2008) Evaluating the evidence for assessing BNP and NT-proBNP levels. Clinical Biochemistry 41:4-5, 227-230
CrossRef159
Darshan Godkar, Kalyan Bachu, Bijal Dave, Selva Niranjan, Ashok Khanna. (2008) B-Type Natriuretic Peptide (BNP) and ProBNP: Role of Emerging Markers to Guide Therapy and Determine Prognosis in Cardiovascular Disorders. American Journal of Therapeutics 15:2, 150-156
CrossRef160
Gino Soldati, Luna Gargani, Fernando R. Silva. (2008) Acute heart failure: new diagnostic perspectives for the emergency physician. Internal and Emergency Medicine 3:1, 37-41
CrossRef161
Debra L Isaac. (2008) Biomarkers in heart failure management. Current Opinion in Cardiology 23:2, 127-133
CrossRef162
Patrick J Gallegos, Eric J MacLaughlin, Krystal K Haase. (2008) Serial Monitoring of Brain Natriuretic Peptide Concentrations for Drug Therapy Management in Patients with Chronic Heart Failure. Pharmacotherapy 28:3, 343-355
CrossRef163
Alan S Maisel. (2008) Natriuretic peptide levels: what’s on the horizon?. Future Cardiology 4:2, 107-109
CrossRef164
I. A. Scott, P. B. Greenberg, P. J. Poole. (2008) Cautionary tales in the clinical interpretation of studies of diagnostic tests. Internal Medicine Journal 38:2, 120-129
CrossRef165
RICHARD W. TROUGHTON, JAY RITZEMA-CARTER, M. GARY NICHOLLS. 2008. Role of Neurohormones. , 345-366.
CrossRef166
Torbjørn Omland. (2008) Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. Critical Care Medicine 36:Suppl, S17-S27
CrossRef167
Christian Müller. (2008) The Potential of Cardiac Markers to Improve Patient Management. Journal of Medical Biochemistry 27:2, 109-113
CrossRef168
Lori B. Daniels, Alan S. Maisel. (2007) Natriuretic Peptides. Journal of the American College of Cardiology 50:25, 2357-2368
CrossRef169
Alan B. Storrow, Fred S. Apple, Alan H.B. Wu, Robert L. Jesse, Gary S. Francis, Robert H. Christenson, Christopher P. Cannon, David A. Morrow, L. Kristin Newby, Jan Ravkilde, Wilson Tang. (2007) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. Point of Care: The Journal of Near-Patient Testing & Technology 6:4, 215-222
CrossRef170
A Mark Richards. (2007) Does NT-proBNP testing reduce costs and improve accuracy in the diagnosis of heart failure?. Nature Clinical Practice Cardiovascular Medicine 4:12, 652-653
CrossRef171
Wayne L Miller, Paul V Targonski, Allan S Jaffe. (2007) B-type natriuretic peptides in heart failure: update on clinical applications and limitations. Biomarkers in Medicine 1:4, 503-512
CrossRef172
Christoph M. Birner, Coskun Ulucan, Sabine Fredersdorf, Munhie Rihm, Hannelore Löwel, Jan Stritzke, Heribert Schunkert, Christian Hengstenberg, Stephan Holmer, Günter Riegger, Andreas Luchner. (2007) Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: Superiority of BNP. Cytokine 40:2, 89-97
CrossRef173
M. Christ, A. Thuerlimann, K. Laule, T. Klima, W. Hochholzer, A. P. Perruchoud, C. Mueller. (2007) Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. European Journal of Clinical Investigation 37:11, 834-841
CrossRef174
Robert C Skeate, Ted Eastlund. (2007) Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Current Opinion in Hematology 14:6, 682-687
CrossRef175
Stephan von Haehling, Ewa A. Jankowska, Nils G. Morgenthaler, Corrado Vassanelli, Luisa Zanolla, Piotr Rozentryt, Gerasimos S. Filippatos, Wolfram Doehner, Friedrich Koehler, Jana Papassotiriou, Dimitrios T. Kremastinos, Waldemar Banasiak, Joachim Struck, Piotr Ponikowski, Andreas Bergmann, Stefan D. Anker. (2007) Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure. Journal of the American College of Cardiology 50:20, 1973-1980
CrossRef176
Rasmus Mogelvang, Jens P. Goetze, Peter Schnohr, Peter Lange, Peter Sogaard, Jens F. Rehfeld, Jan S. Jensen. (2007) Discriminating Between Cardiac and Pulmonary Dysfunction in the General Population With Dyspnea by Plasma Pro-B-Type Natriuretic Peptide. Journal of the American College of Cardiology 50:17, 1694-1701
CrossRef177
Christian Mueller. (2007) B-Type Natriuretic Peptides and the General Practitioner
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 50:17, 1702-1703
CrossRef178
Christian Mueller. (2007) The use of B-type natriuretic peptides in the intensive care unit*. Critical Care Medicine 35:10, 2438-2439
CrossRef179
Ali Ahmed. (2007) DEFEAT Heart Failure: Clinical Manifestations, Diagnostic Assessment, and Etiology of Geriatric Heart Failure. Heart Failure Clinics 3:4, 389-402
CrossRef180
Michel Zuber, Peter Kipfer, Christine H. Attenhofer Jost. (2007) Usefulness of Acoustic Cardiography to Resolve Ambiguous Values of B-Type Natriuretic Peptide Levels in Patients With Suspected Heart Failure. The American Journal of Cardiology 100:5, 866-869
CrossRef181
JOSEPH D. TOBIAS, CHRISTOPHER L. LINDBLADE, MARCUS S. SCHAMBERGER. (2007) B-type natriuretic peptide monitoring in the Pediatric ICU population. Pediatric Anesthesia 17:8, 793-799
CrossRef182
Senay Arikan, Alpaslan Tuzcu, Deniz Gokalp, Mithat Bahceci, Ramazan Danis. (2007) Hyperthyroidism may affect serum N-terminal pro-B-type natriuretic peptide levels independently of cardiac dysfunction. Clinical Endocrinology 67:2, 202-207
CrossRef183
A M Abdulle, N J D Nagelkerke, A Adem, S Abouchacra, J Y Pathan, M Al-Rukhaimi, M N Suleiman, M C Mathew, M G Nicholls, E N Obineche. (2007) Plasma N terminal pro-brain natriuretic peptide levels and its determinants in a multi-ethnic population. Journal of Human Hypertension 21:8, 647-653
CrossRef184
D. M. Musher, A. M. Rueda, A. S. Kaka, S. M. Mapara. (2007) The Association between Pneumococcal Pneumonia and Acute Cardiac Events. Clinical Infectious Diseases 45:2, 158-165
CrossRef185
Sukesh C. Burjonroppa, Ann T. Tong, Lian-Chun Xiao, Marcella M. Johnson, S Wamique Yusuf, Daniel J. Lenihan. (2007) Cancer Patients With Markedly Elevated B-Type Natriuretic Peptide May Not Have Volume Overload. American Journal of Clinical Oncology 30:3, 287-293
CrossRef186
Samuel J. McClure, Scott Gall, Clyde B. Schechter, Mark Kearney, Azfar G. Zaman. (2007) Percutaneous Coronary Revascularization Reduces Plasma N-Terminal Pro-B-Type Natriuretic Peptide Concentration in Stable Coronary Artery Disease. Journal of the American College of Cardiology 49:25, 2394-2397
CrossRef187
Scott M. Silvers, John M. Howell, Joshua M. Kosowsky, Ivan C. Rokos, Andy S. Jagoda. (2007) Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Acute Heart Failure Syndromes. Annals of Emergency Medicine 49:5, 627-669
CrossRef188
Michael A. Burke, William G. Cotts. (2007) Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Failure Reviews 12:1, 23-36
CrossRef189
Fredric Ginsberg, Simon Topalian. (2007) Natriuretic peptides: Biomarkers not predictive in the intensive care unit. Critical Care Medicine 35:4, 1194-1195
CrossRef190
Teresa C. DeFrancesco, John E. Rush, Elizabeth A. Rozanski, Bernard D. Hansen, Bruce W. Keene, Dominic T. Moore, Clarke E. Atkins. (2007) Prospective Clinical Evaluation of an ELISA B-Type Natriuretic Peptide Assay in the Diagnosis of Congestive Heart Failure in Dogs Presenting with Cough or Dyspnea. Journal of Veterinary Internal Medicine 21:2, 243-250
CrossRef191
S. M. Marcovina, F. Crea, J. Davignon, J. C. Kaski, W. Koenig, U. Landmesser, P. L. Pieri, J. Schulz-Menger, L. J. Shaw, J. Sobesky. (2007) Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools. Journal of Internal Medicine 261:3, 214-234
CrossRef192
Michael Christ, Yulia Sharkova, Hendrik Fenske, Sven Rostig, Ileana Herzum, Heinrich F. Becker, Christian Mueller, Wolfram Grimm. (2007) Brain natriuretic peptide for prediction of Cheyne-Stokes respiration in heart failure patients. International Journal of Cardiology 116:1, 62-69
CrossRef193
James L. Januzzi, Carlos A. Camargo, Roderick Tung. (2007) Response to “Getting the Right Message”. Annals of Emergency Medicine 49:3, 381-383
CrossRef194
Anil-Martin Sinha, Ole-Alexander Breithardt, Johannes Brachmann. (2007) Brain natriuretic peptide: does it play a role in post-cardiac surgery patients?. Future Cardiology 3:2, 109-113
CrossRef195
John R. Kapoor, Mark A. Perazella. (2007) Diagnostic and Therapeutic Approach to Acute Decompensated Heart Failure. The American Journal of Medicine 120:2, 121-127
CrossRef196
Ali Ahmed. (2007) Clinical Manifestations, Diagnostic Assessment, and Etiology of Heart Failure in Older Adults. Clinics in Geriatric Medicine 23:1, 11-30
CrossRef197
Ji Yong Choi. (2007) The Role of Brain Natriuretic Peptide in the Patients with Acute Dyspnea in the Emergency Department. Korean Circulation Journal 37:10, 464
CrossRef198
J. Malcolm O. Arnold, Jonathan G. Howlett, Paul Dorian, Anique Ducharme, Nadia Giannetti, Haissam Haddad, George A. Heckman, Andrew Ignaszewski, Debra Isaac, Philip Jong, Peter Liu, Elizabeth Mann, Robert S. McKelvie, Gordon W. Moe, John D. Parker, Anna M. Svendsen, Ross T. Tsuyuki, Kelly O’Halloran, Heather J. Ross, Vivek Rao, Errol J. Sequeira, Michel White. (2007) Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Canadian Journal of Cardiology 23:1, 21-45
CrossRef199
Amiram Nir. (2007) ABCs of Natriuretic Peptides: Cardiac Aspects. Hormone Research 67:1, 77-80
CrossRef200
W. H. Wilson Tang. (2007) B-Type Natriuretic Peptide: A Critical Review. Congestive Heart Failure 13:1, 48-52
CrossRef201
Patrick B. Mark, Colin J. Petrie, Alan G. Jardine. (2007) Diagnostic, Prognostic, and Therapeutic Implications of Brain Natriuretic Peptide in Dialysis and Nondialysis-Dependent Chronic Renal Failure. Seminars in Dialysis 20:1, 40-49
CrossRef202
Peter Matt, Thierry Carrel, Melanie White, Ivan Lefkovits, Jennifer Van Eyk. (2007) Proteomics in cardiovascular surgery. The Journal of Thoracic and Cardiovascular Surgery 133:1, 210-214.e1
CrossRef203
2007. H. , 90-108.
CrossRef204
B. MÜLLER, E. SÜESS, P. SCHUETZ, C. MÜLLER, R. BINGISSER, A. BERGMANN, D. STOLZ, M. TAMM, N. G. MORGENTHALER, M. CHRIST-CRAIN. (2006) Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. Journal of Internal Medicine 260:6, 568-576
CrossRef205
Binhui Ren, Haiwei Wu, Rong Yin, Zhengshan Shi, Jiaquan Zhu, Hua Jing. (2006) N-terminal pro-brain natriuretic peptide predicts the clinical outcome following valve replacement surgery. Clinica Chimica Acta 374:1-2, 149-150
CrossRef206
P. Ray, Y. Lefort. (2006) Intérêt du dosage des peptides natriurétiques en urgence. La Revue de Médecine Interne 27:11, 858-864
CrossRef207
Michael Christ, Kirsten Laule-Kilian, Willibald Hochholzer, Theresia Klima, Tobias Breidthardt, Andre P. Perruchoud, Christian Mueller. (2006) Gender-Specific Risk Stratification With B-Type Natriuretic Peptide Levels in Patients With AcuteDyspnea. Journal of the American College of Cardiology 48:9, 1808-1812
CrossRef208
C. MUELLER, K. LAULE-KILIAN, T. KLIMA, T. BREIDTHARDT, W. HOCHHOLZER, A. P. PERRUCHOUD, M. CHRIST. (2006) Right bundle branch block and long-term mortality in patients with acute congestive heart failure. Journal of Internal Medicine 260:5, 421-428
CrossRef209
Christian Zugck, Manfred Nelles, Hugo A. Katus, Paul O. Collinson, David C. Gaze, Bert Dikkeschei, Eberhard Gurr, Wiebke Hayen, Markus Haass, Christoph Hechler, Viviane van Hoof, Khadija Guerti, Carl van Waes, Gert Printzen, Kai Klopprogge, Ilse Schulz, Rainer Zerback. (2006) Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood. Clinical Chemistry and Laboratory Medicine 44:10, 1269-1277
CrossRef210
Alan B. Storrow, Christopher J. Lindsell, Sean P. Collins, Greg J. Fermann, Andra L. Blomkalns, Janet M. Williams, Barbara Goldsmith, W. Brian Gibler. (2006) Emergency Department Multimarker Point-of-care Testing Reduces Time to Cardiac Marker Results Without Loss of Diagnostic Accuracy. Point of Care: The Journal of Near-Patient Testing & Technology 5:3, 132-136
CrossRef211
Gordon W Moe. (2006) B-type natriuretic peptide in heart failure. Current Opinion in Internal Medicine 5:4, 385-391
CrossRef212
Alain Rudiger, Stefan Gasser, Manuel Fischler, Thorsten Hornemann, Arnold von Eckardstein, Marco Maggiorini. (2006) Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure*. Critical Care Medicine 34:8, 2140-2144
CrossRef213
Alfons Gegenhuber, Thomas Mueller, Benjamin Dieplinger, Werner Poelz, Richard Pacher, Meinhard Haltmayer. (2006) B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clinica Chimica Acta 370:1-2, 174-179
CrossRef214
Michel Zuber, Peter Kipfer, Christine Attenhofer Jost. (2006) Systolic Dysfunction: Correlation of Acoustic Cardiography With Doppler Echocardiography. Congestive Heart Failure 12, 14-18
CrossRef215
John M. Costello, Denise M. Goodman, Thomas P. Green. (2006) A review of the natriuretic hormone system??s diagnostic and therapeutic potential in critically ill children*. Pediatric Critical Care Medicine 7:4, 308-318
CrossRef216
W. Frank Peacock. (2006) Acoustic Cardiography in the Differential Diagnosis of Dyspnea. Congestive Heart Failure 12:s4, 41-43
CrossRef217
Michel Zuber, Peter Kipfer, Christine Attenhofer Jost. (2006) Systolic Dysfunction: Correlation of Acoustic Cardiography With Doppler Echocardiography. Congestive Heart Failure 12:s4, 14-18
CrossRef218
Daniel P. Schuster. (2006) Is measuring B-type natriuretic peptide in critically ill patients ever useful?*. Critical Care Medicine 34:7, 2019-2020
CrossRef219
W. Frank Peacock. (2006) Acoustic Cardiography in the Differential Diagnosis of Dyspnea. Congestive Heart Failure 12, 41-43
CrossRef220
D Conen, M Pfisterer, B Martina. (2006) Substantial intraindividual variability of BNP concentrations in patients with hypertension. Journal of Human Hypertension 20:6, 387-391
CrossRef221
Élie Azoulay, Benoît Schlemmer. (2006) Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Medicine 32:6, 808-822
CrossRef222
Yaniv Almog, Victor Novack, Rinat Megralishvili, Sergio Kobal, Leonid Barski, Daniel King, Doron Zahger. (2006) Plasma Level of N Terminal Pro-Brain Natriuretic Peptide as a Prognostic Marker in Critically Ill Patients. Anesthesia & Analgesia 102:6, 1809-1815
CrossRef223
Lori B. Daniels, Vikas Bhalla, Paul Clopton, Judd E. Hollander, David Guss, Peter A. McCullough, Richard Nowak, Gary Green, Mitchell Saltzberg, Stefanie R. Ellison, Meenakshi Awasthi Bhalla, Robert Jesse, Alan Maisel. (2006) B-Type Natriuretic Peptide (BNP) Levels and Ethnic Disparities in Perceived Severity of Heart Failure. Journal of Cardiac Failure 12:4, 281-285
CrossRef224
Melvin R. Pratter, Thaddeus Bartter, Stephen M. Akers, Jonathan Kass. (2006) A Clinical Approach to Chronic Dyspnea. Clinical Pulmonary Medicine 13:3, 149-163
CrossRef225
Robert Chircop, George A Jelinek. (2006) B-type natriuretic peptide in the diagnosis of heart failure in the emergency department. Emergency Medicine Australasia 18:2, 170-179
CrossRef226
A.-M. Sinha, O.-A. Breithardt. (2006) Sind neurohumorale Blutparameter wegweisend für die Effizienz der kardialen Resynchronisationstherapie?. Herzschrittmachertherapie & Elektrophysiologie 17:S1, i51-i55
CrossRef227
Marc A Silver. (2006) The natriuretic peptide system: kidney and cardiovascular effects. Current Opinion in Internal Medicine 5:2, 203-210
CrossRef228
C. Mueller, K. Laule-Kilian, A. Christ, A. P. Perruchoud. (2006) The use of B-type natriuretic peptide in the management of patients with diabetes and acute dyspnoea. Diabetologia 49:4, 629-636
CrossRef229
Susan Isakson, Alan Maisel. (2006) Update on Natriuretic Peptides. Point of Care: The Journal of Near-Patient Testing & Technology 5:1, 6-12
CrossRef230
Peter A. McCullough, Christian Mueller, Clyde W. Yancy. (2006) Overview of B-Type Natriuretic Peptide as a Blood Test. Congestive Heart Failure 12:2, 99-102
CrossRef231
Aaron L. Baggish, James L. Januzzi. (2006) Cost Effectiveness of Natriuretic Peptide Measurement in the Primary Care Setting: Have We Found the Gatekeeper for the Evaluation of Dyspneic Outpatients?. Congestive Heart Failure 12:2, 108-109
CrossRef232
Nancy M. Albert. (2006) They??re Watching You!. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 5:1, 18-24
CrossRef233
Paul O. Collinson. (2006) The Cost Effectiveness of B-Type Natriuretic Peptide Measurement in the Primary Care Setting?A UK Perspective. Congestive Heart Failure 12:2, 103-107
CrossRef234
Raymond C. Roy. (2006) What Is New in Geriatric Anesthesia?. ASA Refresher Courses in Anesthesiology 34:1, 139-150
CrossRef235
Alan S Maisel, Vikas Bhalla, Eugene Braunwald. (2006) Cardiac biomarkers: a contemporary status report. Nature Clinical Practice Cardiovascular Medicine 3:1, 24-34
CrossRef236
Yu-Sheng Lin, Pao-Hsien Chu, Ming-Chung Kuo, Shih-Ming Jung, Kun-Eng Lim, Chi-Tai Kuo, Lee-Yung Shih. (2006) Use of a B-Type Natriuretic Peptide in Evaluating the Treatment Response of a Relapsed Lymphoma with Cardiac Involvement. International Journal of Hematology 83:1, 44-46
CrossRef237
Ostidimma Ugwu, George Chrysochoou, Manjule Ashok, Jennifer Waxler, Daniel Shine. (2006) Assigning Patients With Heart Failure to Observation Status: B-Type Natriuretic Peptide, Ejection Fraction, or Physician Judgment. Congestive Heart Failure 12:1, 26-31
CrossRef238
M.P. Sanz, L. Borque, A. Rus, B. Vicente, Y. Ramírez, L. Lasa. (2006) Comparison of BNP and NT-proBNP assays in the approach to the emergency diagnosis of acute dyspnea. Journal of Clinical Laboratory Analysis 20:6, 227-232
CrossRef239
Mark Richards, M. Gary Nicholls, Eric A. Espiner, John G. Lainchbury, Richard W. Troughton, John Elliott, Christopher M. Frampton, Ian G. Crozier, Timothy G. Yandle, Robert Doughty, Stephen MacMahon, Norman Sharpe. (2006) Comparison of B-Type Natriuretic Peptides for Assessment of Cardiac Function and Prognosis in Stable Ischemic Heart Disease. Journal of the American College of Cardiology 47:1, 52-60
CrossRef240
S Beer, S Golay, D Bardy, F Feihl, RC Gaillard, C Bachmann, B Waeber, J Ruiz. (2005) Increased plasma levels of N-terminal brain natriuretic peptide (NT-proBNP) in type 2 diabetic patients with vascular complications. Diabetes & Metabolism 31:6, 567-573
CrossRef241
Hao-Min Cheng, Shao-Yuan Chuang, Pai-Feng Hsu, Pesus Chou, Chen-Huan Chen. (2005) Systolic time intervals revisited: correlations with N-terminal pro-brain natriuretic peptide in a community population. Heart and Vessels 20:6, 256-263
CrossRef242
Jennifer M. Aviles, Ronnier J. Aviles. (2005) Advances in Cardiac Biomarkers. Emergency Medicine Clinics of North America 23:4, 959-975
CrossRef243
Martina Zaninotto, Monica Mion, Sara Altinier, Mara Pastorello, Stefano Rocco, Franco Tosato, Sabino Iliceto, Mario Plebani. (2005) NT-proBNP in the differential diagnosis of acute dyspnea in the emergency department. Clinical Biochemistry 38:11, 1041-1044
CrossRef244
Domingo A. Pascual Figal, María C. Cerdán Sánchez, José A. Noguera Velasco, Teresa Casas Pina, Luis Muñoz Gimeno, Rosa García Rodríguez, Juan A. Ruipérez Abizanda, Pedro Martínez Hernández, Mariano Valdés Chávarri. (2005) Utilidad del NTproBNP en el manejo urgente del paciente con disnea severa y diagnóstico dudoso de insuficiencia cardíaca. Revista Española de Cardiología 58:10, 1155-1161
CrossRef245
U. Wagner, C. Vogelmeier. (2005) Akute Dyspnoe. Der Internist 46:9, 965-973
CrossRef246
Sharon Ann Hunt. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology 46:6, e1-e82
CrossRef247
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article. Journal of the American College of Cardiology 46:6, 1116-1143
CrossRef248
Jonathan G Howlett. (2005) Acutely decompensated congestive heart failure: new therapies for an old problem. Expert Review of Cardiovascular Therapy 3:5, 925-936
CrossRef249
Stephane Arques, Emmanuel Roux, Pascal Sbragia, Pierre Ambrosi, Lionel Taieb, Bertrand Pieri, Richard Gelisse, Roger Luccioni. (2005) Accuracy of Tissue Doppler Echocardiography in the Emergency Diagnosis of Decompensated Heart Failure with Preserved Left Ventricular Systolic Function: Comparison with B-Type Natriuretic Peptide Measurement. Echocardiography 22:8, 657-664
CrossRef250
Phua Jason, Lim Tow Keang, Lee Kang Hoe. (2005) B-type natriuretic peptide: Issues for the intensivist and pulmonologist. Critical Care Medicine 33:9, 2094-2013
CrossRef251
U. C. Hoppe, M. Böhm, R. Dietz, P. Hanrath, H. K. Kroemer, A. Osterspey, A. A. Schmaltz, E. Erdmann. (2005) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Zeitschrift für Kardiologie 94:8, 488-509
CrossRef252
Dirk Peetz, Gerd Hafner, Karl J. Lackner. (2005) Patientennahe Bestimmung natriuretischer Peptide Near-patient testing of natriuretic peptides. LaboratoriumsMedizin 29:4, 219-228
CrossRef253
Julia Kirchheiner, Uwe Fuhr, Jürgen Brockmöller. (2005) Opinion: Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?. Nature Reviews Drug Discovery 4:8, 639-647
CrossRef254
James K McCord. (2005) Cardiac markers in acute coronary syndrome. Future Cardiology 1:4, 489-494
CrossRef255
Jos?? Manuel Porcel. (2005) The use of probrain natriuretic peptide in pleural fluid for the diagnosis of pleural effusions resulting from heart failure. Current Opinion in Pulmonary Medicine 11:4, 329-333
CrossRef256
T. Bocek, N. G. Morgenthaler, D. Staub, C. Nusbaumer, A. Christ, M. J. Zellweger, J. Mueller-Brand, B. Mueller, A. P. Perruchoud, C. Mueller. (2005) Use of pro-atrial natriuretic peptide in the detection of myocardial ischaemia. European Journal of Clinical Investigation 35:7, 450-456
CrossRef257
C. MUELLER, K. LAULE-KILIAN, B. FRANA, D. RODRIGUEZ, J. RUDEZ, A. SCHOLER, P. BUSER, M. PFISTERER, A. P. PERRUCHOUD. (2005) The use of B-type natriuretic peptide in the management of elderly patients with acute dyspnoea. Journal of Internal Medicine 258:1, 77-85
CrossRef258
A. Mark Richards, Richard Troughton, John Lainchbury, Rob Doughty, Sue Wright. (2005) Guiding and Monitoring of Heart Failure Therapy With NT-ProBNP: Concepts and Clinical Studies. Journal of Cardiac Failure 11:5, S34-S37
CrossRef259
J.Á. Rodríguez Fernández, I.P. Garrido Bravo, L.F. Hermida Álvarez, A. Castro Beiras. (2005) Insuficiencia cardíaca crónica. Etiología, manifestaciones clínicas y criterios diagnósticos. Medicine - Programa de Formación Médica Continuada Acreditado 9:35, 2300-2307
CrossRef260
Mira Barak, Ronit Weinberger, Jerom Marcusohn, Paul Froom. (2005) Harmonization of the Bayer ADVIA Centaur and Abbott AxSYM automated B-type natriuretic peptide assay in patients on hemodialysis. Clinical Chemistry and Laboratory Medicine 43:5, 554-556
CrossRef261
Douglas S Lee, Ramachandran S Vasan. (2005) Novel markers for heart failure diagnosis and prognosis. Current Opinion in Cardiology 20:3, 201-210
CrossRef262
Wolfgang G Toller, Helfried Metzler. (2005) Acute perioperative heart failure. Current Opinion in Anaesthesiology 18:2, 129-135
CrossRef263
Peter Cameron, Henry Krum. (2005) Chronic heart failure. Emergency Medicine Australasia 17:2, 99-101
CrossRef264
Albertus Beishuizen, Koen J. Hartemink, István Vermes, AB Johan Groeneveld. (2005) Circulating cardiovascular markers and mediators in acute illness: an update. Clinica Chimica Acta 354:1-2, 21-34
CrossRef265
Patrick Ray, Martine Arthaud, Sophie Birolleau, Richard Isnard, Yannick Lefort, Jacques Boddaert, Bruno Riou, . (2005) Comparison of Brain Natriuretic Peptide and Probrain Natriuretic Peptide in the Diagnosis of Cardiogenic Pulmonary Edema in Patients Aged 65 and Older. Journal of the American Geriatrics Society 53:4, 643-648
CrossRef266
Mandeep R. Mehra, Alan Maisel. (2005) B-Type Natriuretic Peptide in Heart Failure. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 4:1, 10-20
CrossRef267
Alpesh N Amin. (2005) The Role of Hospitalists in the Management of Acute Decompensated Heart Failure. The American Heart Hospital Journal 3:2, 111-117
CrossRef268
Alan Maisel, Mandeep R. Mehra. (2005) Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. Clinical Cornerstone 7, S7-S17
CrossRef269
Cara A Wasywich, Gillian A Whalley, Robert N Doughty. (2005) Brain natriuretic peptide in the contemporary management of congestive heart failure. Expert Review of Cardiovascular Therapy 3:1, 71-84
CrossRef270
L. Tarnow, P. Hildebrandt, B. V. Hansen, K. Borch-Johnsen, H.-H. Parving. (2005) Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 48:1, 149-155
CrossRef271
Hormaz Dastoor, Bassam Bernieh, Yousef Boobes, Samra Abouchacra, Elhadi Eltayeb, Mustafa Nur Elhuda, Elsadig Kazzam, Enyioma N Obineche, M Gary Nicholls. (2005) Plasma BNP in patients on maintenance haemodialysis. Journal of Hypertension 23:1, 23-28
CrossRef272
Christian Mueller, Kirsten Laule-Kilian, Andre Scholer, Charly Nusbaumer, Thomas Zeller, Daniel Staub, Andre P. Perruchoud. (2005) B-type natriuretic peptide for acute dyspnea in patients with kidney disease: Insights from a randomized comparison. Kidney International 67:1, 278-284
CrossRef273
John V Wylie, Lana Tsao. (2004) Nesiritide for the treatment of decompensated heart failure. Expert Review of Cardiovascular Therapy 2:6, 803-813
CrossRef274
R. Pfister, C.A. Schneider. (2004) Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives?. Clinica Chimica Acta 349:1-2, 25-38
CrossRef275
AJ Marian, Vijay Nambi. (2004) Biomarkers of cardiac disease. Expert Review of Molecular Diagnostics 4:6, 805-820
CrossRef276
Stefan W Suttner, Joachim Boldt. (2004) Natriuretic peptide system: physiology and clinical utility. Current Opinion in Critical Care 10:5, 336-341
CrossRef277
(2004) Congress of Clinical Chemistry and Laboratory Medicine Annual meeting of the German United Society for Clinical Chemistry and Laboratory Medicine (DGKL), Düsseldorf, Germany, November 22-24, 2004. Clinical Chemistry and Laboratory Medicine 42:10, A101-A161
CrossRef278
Torbjørn Omland. (2004) Heart failure in the emergency department. Journal of the American College of Cardiology 44:6, 1334-1336
CrossRef279
Michael J. Gallagher, Peter A. McCullough. (2004) The emerging role of natriuretic peptides in the diagnosis and treatment of decompensated heart failure. Current Heart Failure Reports 1:3, 129-135
CrossRef280
James Kevin McCord. (2004) The Future of Cardiac Markers in the Emergency Department. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 3:3, 107-109
CrossRef281
Clyde W. Yancy, John C. Burnett, Gregg C. Fonarow, Marc A. Silver. (2004) Decompensated Heart Failure: Is There a Role for the Outpatient Use of Nesiritide?. Congestive Heart Failure 10:5, 230-236
CrossRef282
Alan Maisel, Judd E. Hollander, David Guss, Peter McCullough, Richard Nowak, Gary Green, Mitchell Saltzberg, Stefanie R. Ellison, Meenakshi Awasthi Bhalla, Vikas Bhalla, Paul Clopton, Robert Jesse. (2004) Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). Journal of the American College of Cardiology 44:6, 1328-1333
CrossRef283
Marc A. Silver, Alan Maisel, Clyde W. Yancy, Peter A. McCullough, John C. Burnett, Gary S. Francis, Mandeep R. Mehra, Gregg Fonarow, W. Brian Gibler, David A. Morrow, Judd Hollander. (2004) BNP Consensus Panel 2004: A Clinical Approach for the Diagnostic, Prognostic, Screening, Treatment Monitoring, and Therapeutic Roles of Natriuretic Peptides in Cardiovascular Diseases. Congestive Heart Failure 10:s5, 1-30
CrossRef284
Richard J. Rodeheffer. (2004) Measuring plasma B-type natriuretic peptide in heart failure. Journal of the American College of Cardiology 44:4, 740-749
CrossRef285
(2004) B-Type Natriuretic Peptide in the Evaluation of Acute Dyspnea. New England Journal of Medicine 350:23, 2416-2417
Full Text286
Zaid Abassi, Tony Karram, Samer Ellaham, Joseph Winaver, Aaron Hoffman. (2004) Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacology & Therapeutics 102:3, 223-241
CrossRef287
John E. Strobeck, Marc A. Silver. (2004) Beyond the Four Quadrants: The Critical and Emerging Role of Impedance Cardiography in Heart Failure. Congestive Heart Failure 10:s2, 1-6
CrossRef288
Mark, Daniel B., Felker, G. Michael, . (2004) B-Type Natriuretic Peptide — A Biomarker for All Seasons?. New England Journal of Medicine 350:7, 718-720
Full Text
- Letters
